Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › carfilzomib

carfilzomib

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of carfilzomib

54 trials tracked of carfilzomib: 10 in phase 3 or 4 and 7 with published results. The most-cited published study has 419 citations.

54Trials tracked
10Phase 3 & 4
0Recruiting
7With published results
Phase distribution
Phase 4 1 Phase 3 9 Phase 2 37 Phase 1 7
  1. Phase 3 Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma. Completed · 419 cited
  2. Phase 3 Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients Completed · 378 cited
  3. Phase 3 Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma Completed · 206 cited
  4. Phase 3 Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma Completed · 129 cited
  5. Phase 3 Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma Completed · 11 cited
  6. Phase 3 A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma Completed · 11 cited
Show 44 more trials
  1. Phase 4 A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy Completed · 2 cited
  2. Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma Completed
  3. Phase 3 A Study of Carfilzomib vs Best Supportive Care in Subjects With Relapsed and Refractory Multiple Myeloma Completed
  4. Phase 3 Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients Completed
  5. Phase 2 Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients Completed
  6. Phase 2 LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma Completed
  7. Phase 2 Phase 1b/2 Study of Carfilzomib, Carboplatin, and Etoposide in Patients With Previously Untreated Extensive Stage Small-cell Lung Cancer Completed
  8. Phase 2 Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma Completed
  9. Phase 2 Phase 2 Trial of Carfilzomib for Metastatic Castration-resistant Prostate Cancer Following Treatment Completed
  10. Phase 2 A Dose Escalation Study of Carfilzomib Taken With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis Completed
  11. Phase 2 Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients Completed
  12. Phase 2 Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma Completed
  13. Phase 2 Infusional Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma Completed
  14. Phase 2 Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma Completed
  15. Phase 2 Carfilzomib, Rituximab and Dexamethasone in Waldenstrom's Macroglobulinemia Completed
  16. Phase 2 Study of High Dose Carfilzomib in Multiple Myeloma Patients Who Have Progressed On Standard Dose Carfilzomib Completed
  17. Phase 2 Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies Completed
  18. Phase 2 Carfilzomib, Rituximab, and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Lymphoma Completed
  19. Phase 2 A Study of Weekly Carfilzomib in Combination With Dexamethasone for Progressive Multiple Myeloma Completed
  20. Phase 2 S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma Completed
  21. Phase 2 A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens Completed
  22. Phase 2 Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Active Multiple Myeloma Completed
  23. Phase 2 Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers Completed
  24. Phase 2 Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma Completed
  25. Phase 2 High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma Completed
  26. Phase 2 Carfilzomib in Refractory Renal Cell Carcinoma (RCC) Completed
  27. Phase 2 Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma Completed
  28. Phase 2 Carfilzomib and Melphalan Before Stem Cell Transplant in Treating Patients With Multiple Myeloma Completed
  29. Phase 2 Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation Completed
  30. Phase 2 Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma Completed
  31. Phase 2 Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas Completed
  32. Phase 2 Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet Completed
  33. Phase 2 Study of the Safety and Pharmacokinetics of Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal Function Completed
  34. Phase 2 A Phase II Study of Carfilzomib in Relapsed Waldenström's Macroglobulinemia (WM) IST-CAR-531 Completed
  35. Phase 2 Study of BTK Inhibitor, Ibrutinib in Combination With Carfilzomib in Subjects With Relapsed and Refractory Multiple Myeloma Completed
  36. Phase 2 Combination Therapy With Carfilzomib for the Antibody-Mediated Rejection Diagnosis in Lung Transplantation Completed
  37. Phase 2 High Dose Carfilzomib for Newly Diagnosed Myeloma Completed
  38. Phase 2 Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma Completed
  39. Phase 2 Carfilzomib in Treating Patients With Chronic Graft-Versus-Host Disease Completed
  40. Phase 2 Carfilzomib, Pegylated Liposomal Doxorubicin Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Completed
  41. Phase 2 A Study of Extended Carfilzomib Therapy for Patients Previously Enrolled in Carfilzomib Treatment Protocols Completed
  42. Phase 1 A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects Completed
  43. Phase 1 Phase 1b Multicenter Study of Carfilzomib With Lenalidomide and Dexamethasone in Relapsed Multiple Myeloma Completed
  44. Phase 1 Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Multiple Myeloma and Renal Disease Completed

Showing the 50 most-cited and recently-updated of 54 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Carfilzomib-lenalidomide-dexamethasone improves progression-free survival versus lenalidomide after transplant in multiple myeloma
Oncology RCT
Carfilzomib-lenalidomide-dexamethasone improves progression-free survival versus lenalidomide after transplant in multiple myeloma Adding carfilzomib to lenalidomide improved survival in multiple myeloma patients after stem cell transplant
In a phase 3 trial of 180 patients with newly diagnosed multiple myeloma after autologous HSCT, carfilzomib-lenalidomide-dexamethasone maint…
Adding carfilzomib to lenalidomide after stem cell transplant boosted four-year survival to 67.5% compared to 38.0% for patients on lenalido…
Apr 9, 2026